BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32583728)

  • 21. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
    Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
    Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia.
    Zhang L; Yang XM; Chen J; Hu L; Yang F; Zhou Y; Zhao BB; Zhao W; Zhu XF
    Drug Des Devel Ther; 2021; 15():1633-1640. PubMed ID: 33911851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).
    Zhang Y; Wang L; Zhang R; Qi P; Xie J; Shi H; Lin W; Wu Y; Yu J; Fan J; Feng G; Zheng H; Wu M
    Pediatr Hematol Oncol; 2019 Oct; 36(7):399-409. PubMed ID: 31530209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell transcriptomics profiling the compatibility mechanism of As
    Zhang X; Chen H; Huang X; Xu H; Li Y; Yuan H; Yu J; Gao Y
    Biomed Pharmacother; 2022 Jul; 151():113182. PubMed ID: 35643069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
    Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
    J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
    Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial.
    Luo S; Tian J; Sun X; Wu F; Liu Y; Wan W; She Z; Wen C
    Evid Based Complement Alternat Med; 2022; 2022():8314176. PubMed ID: 35836830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
    Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of acute promyelocytic leukemia in a 92-year-old man using all-trans retinoic acid combined with oral arsenic: A case report.
    Shi X; Li S; Tang S; Lu Y
    Medicine (Baltimore); 2021 Jun; 100(22):e26144. PubMed ID: 34087869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
    Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
    Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.
    Huang Q; Wang T; Xiong Y; Qu L; Yin Q; Zou W
    Chin Herb Med; 2022 Jan; 14(1):154-165. PubMed ID: 36120125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
    Zhang X; Yang L; Qiao Z
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
    Ma Y; Liu L; Jin J; Lou Y
    PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.